Skip to main content
. Author manuscript; available in PMC: 2019 Aug 11.
Published in final edited form as: Nat Metab. 2019 Feb 11;1(2):291–303. doi: 10.1038/s42255-018-0030-7

Figure 2.

Figure 2.

Recombinant TGF-β2 treatment stimulates glucose uptake and oxygen consumption rate (OCR) in vitro. (a) Glucose uptake in C2C12 myotubes, 3T3-L1 adipocytes, and WT-1 brown adipocytes treated with TGF-β2; n=6 biological replicates for C2C12 myotubes and 3T3-L1 adipocytes. n=9 biological replicates for WT-1 brown adipocytes. (b) [14C] palmitic acid uptake and oxidation in C2C12 myotubes, 3T3-L1 adipocytes and WT-1 brown adipocytes treated with TGF-β2; n = 6 biological replicates. (c) Extracellular flux analysis in C2C12 myotubes treated with TGF-β1, TGF-β2, or TGF-β3. n=4–6 technical-replicates wells. (d) Ppargc1a mRNA expression in C2C12 myotubes, 3T3-L1 adipocytes, and WT-1 brown adipocytes treated with TGF-β2; n=3 biological replicates. Data are presented as box plots (min, max, median, and 25th and 75th percentiles) with dots as individual values (a, b and c), or mean ± s.e.m (c). Unpaired two-tailed Student’s t-test was used for a, b and d.